NO953961L - Antihypertriglyseridemisk sammensetning - Google Patents

Antihypertriglyseridemisk sammensetning

Info

Publication number
NO953961L
NO953961L NO953961A NO953961A NO953961L NO 953961 L NO953961 L NO 953961L NO 953961 A NO953961 A NO 953961A NO 953961 A NO953961 A NO 953961A NO 953961 L NO953961 L NO 953961L
Authority
NO
Norway
Prior art keywords
hypertriglyceride
epidemic
composition
hypertriglyceride epidemic
epidemic composition
Prior art date
Application number
NO953961A
Other languages
English (en)
Other versions
NO308580B1 (no
NO953961D0 (no
Inventor
Yasuo Sugiyama
Hidefumi Yukimasa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO953961D0 publication Critical patent/NO953961D0/no
Publication of NO953961L publication Critical patent/NO953961L/no
Publication of NO308580B1 publication Critical patent/NO308580B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO953961A 1994-10-07 1995-10-05 Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin NO308580B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24413694 1994-10-07

Publications (3)

Publication Number Publication Date
NO953961D0 NO953961D0 (no) 1995-10-05
NO953961L true NO953961L (no) 1996-04-09
NO308580B1 NO308580B1 (no) 2000-10-02

Family

ID=17114301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953961A NO308580B1 (no) 1994-10-07 1995-10-05 Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin

Country Status (11)

Country Link
EP (1) EP0705607A2 (no)
KR (1) KR960013370A (no)
CN (1) CN1128657A (no)
AU (1) AU703422B2 (no)
CA (1) CA2160092A1 (no)
FI (1) FI954773A7 (no)
HU (1) HUT73422A (no)
NO (1) NO308580B1 (no)
NZ (1) NZ280165A (no)
RU (1) RU2166320C2 (no)
TW (1) TW401301B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2158344T3 (es) * 1995-09-13 2001-09-01 Takeda Chemical Industries Ltd Compuestos benzoxazepinicos, su produccion y uso como agentes reductores de lipidos.
CN1072649C (zh) * 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
WO1997047323A2 (en) * 1996-06-11 1997-12-18 Zonagen, Inc. Chitosan drug delivery system
ATE309993T1 (de) 1997-04-21 2005-12-15 Takeda Pharmaceutical 4,1-benzoxazepine, ihre analoga, und ihre verwendung als somatostatin-agonisten
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
US6214991B1 (en) 1998-03-31 2001-04-10 The Institute For Pharmaceutical Discovery, Inc. Substituted indolealkanoic acids
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
CA2370141A1 (en) 1999-05-26 2000-12-07 James D. Rodgers 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
WO2002038180A1 (en) * 2000-11-09 2002-05-16 Takeda Chemical Industries, Ltd. High-density lipoprotein-cholesterol level elevating agent
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US20040204500A1 (en) * 2001-06-28 2004-10-14 Yasuo Sugiyama Preventives/remedies for organ functional disorders and organ dysfunction
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US7625887B2 (en) 2003-01-28 2009-12-01 Takeda Pharmaceutical Company Limited Receptor agonists
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
CA2575014A1 (en) * 2004-08-09 2006-02-16 Takeda Pharmaceutical Company Limited Crp lowering agent
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
JP2010526825A (ja) 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンゾ−１，４−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
FR2659332B1 (fr) * 1990-03-08 1994-04-29 Adit Et Cie Nouvelles pyrrolo [1,2-a] thieno [3,2-f] diazepines [1,4], leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0567026B1 (en) * 1992-04-20 2003-03-26 Takeda Chemical Industries, Ltd. 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides
TW225992B (no) * 1992-07-17 1994-07-01 Senju Pharma Co
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
WO1995021834A1 (en) * 1994-02-09 1995-08-17 Takeda Chemical Industries, Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors

Also Published As

Publication number Publication date
FI954773A0 (fi) 1995-10-06
HUT73422A (en) 1996-07-29
NO308580B1 (no) 2000-10-02
EP0705607A3 (no) 1996-05-08
HU9502918D0 (en) 1995-11-28
CA2160092A1 (en) 1996-04-08
AU703422B2 (en) 1999-03-25
FI954773A7 (fi) 1996-04-08
KR960013370A (ko) 1996-05-22
RU2166320C2 (ru) 2001-05-10
NZ280165A (en) 1997-07-27
NO953961D0 (no) 1995-10-05
EP0705607A2 (en) 1996-04-10
AU3308195A (en) 1996-04-18
CN1128657A (zh) 1996-08-14
TW401301B (en) 2000-08-11

Similar Documents

Publication Publication Date Title
DE69526966D1 (de) Hautkräftigende kometische zusammensetzung
NO953961D0 (no) Antihypertriglyseridemisk sammensetning
FI974241L (fi) BPM-15 -koostumukset
DE69423670D1 (de) Siloxy-aluminoxan-Zusammensetzungen
BR9508844A (pt) Composição oral
DE69520871D1 (de) Glaszusammensetzungen
ID16251A (id) Komposisi-komposisi pembasmi kuman
BR9508318A (pt) Composição impadora concentrada
BR9506536A (pt) Composição oral
DE69530614D1 (de) Iontophorese pflaster
DE69708866D1 (de) Mikroverkapselte zusammensetzungen
BR9606809A (pt) Composição inseticidamente ativa
BR9607058A (pt) Composição
DE69733072D1 (de) Farbschonende zusammensetzungen
BR9510467A (pt) Composições orais
DE69512397D1 (de) Wärmehärtende zusammensetzung
DE69617029D1 (de) Organoton-zusammensetzungen
NO981568D0 (no) Randtennings-tennsatssammensetninger
DE69719442D1 (de) Frisierschaum-Zusammensetzungen
PT728814E (pt) Composicao betuminosa
BR9510307A (pt) Composições orais
DE69503738D1 (de) Fotopolymerisierbare Zusammensetzung
BR9609903A (pt) ComposiçÃo inseticidamente ativa
BR9707835A (pt) Composiç
ITMI940362A0 (it) Composizione antitosse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2003